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Abstract. We report herein a rare case of massive pleural 
effusion caused by papillary thyroid cancer, which was accom-
panied by multiple pulmonary metastasis. A 91-year-old male 
patient presented with shortness of breath due to massive right 
pleural fluid. Cytological specimens, which were obtained 
from pleural fluid by thoracentesis, and was consistent with that 
observed in surgically resected thyroid cancer 6-year previ-
ously. Immunocytochemical staining of the cells was positive 
for cytokeratin (CK)-7, CK-19, and positive for thyroglobulin. 
Massive pleural fluid due to a metastatic from papillary thyroid 
cancer is very rare but may develop in long-term survivors 
with this disease as observed in this case.
Introduction
Thyroid cancer is not a rare cancer but has a relatively slow 
progression in many patients. However, it may metastasize to 
distant organs including lungs as disease progression. Lung 
metastases of thyroid cancer are those to the lung parenchyma, 
such metastases usually have multiple small nodules in both 
lungs (1,2). On the contrary, however, pleural fluid due to 
thyroid cancer is a rare etiology, to our knowledge, and only 
51 cases have been reported (3‑19). Pleural fluid due to thyroid 
cancer has been reported to be less than 1% in all the patients 
with malignant pleural fluids (4,11). Papillary thyroid cancer 
was the major histologic type of thyroid cancer with pleural 
effusion, and other histologic types were few (3). Thyroid 
cancer patients with pleural fluid, regardless of tissue type, 
were long-term survivors (3-19). In general, diagnosis of 
malignant fluid is established by positive pathological findings 
using specimens from pleural fluid (20). Thoracentesis using 
fine needle is usually used, but in some cases pleural biopsy 
or thoracoscope is performed if the appropriate materials 
cannot be obtained by thoracentesis (21). As for the therapy, 
drainage using thoracic tube is indicative for the patients with 
dyspnea, especially those with chemotherapy-resistant malig-
nancies (22). As for therapy, pleurodesis is usually performed 
after pleural fluid drainage. However, as this is a rare condi-
tion, standard therapy has not yet established. This case report 
documents our clinical experience, we present herein a patient 
with pleural fluid due to papillary thyroid cancer, and reviewed 
previously reported such cases (3-19).
Materials and methods
The study was conducted in the Division of Respiratory 
Medicine, Mito Medical Center, University of Tsukuba and 
approved by the Ethics Committee of Division of Respiratory 
Medicine, Mito Medical Center, University of Tsukuba. An 
informed consent was obtained from the patient included 
in this study. Clinical evaluation of the lesions followed the 
guideline for diagnosis and treatment of the lung cancer (The 
Japan Lung Cancer Society 2018). All cytological specimens 
evaluated in our study underwent needle thoracic puncture 
under local anesthesia. Cytopathological examination was 
performed after standard hematoxylin and eosin staining of 
the specimens. Written informed consent was obtained from 
the patient for publication and this study was approved by the 
research ethics committee of Mito Medical Center, University 
of Tsukuba‑Mito Kyodo General Hospital (νo. 1660). The 
patient was hospitalized from March 2013 to April 2013. 
Computed tomography used Aquilion 64 model manufactured 
by Toshiba Medical Systems (Tokyo, Japan). Cytological spec-
imens obtained from pleural fluid were fixed in 10% buffered 
formalin, embedded in paraffin and stained with HE method 
routinely for histological examination. Immunostaining of 
cytokeratin 7 (CK-7), CK-19, and thyroglobulin was performed 
on thyroid cancer cells obtained from pleural fluid that were 
washed and fixed methanol before treatment with serum‑free 
protein block (Code No. X0909; DAKO Tokyo, Japan). 
These cells were probed with antibodies to CK-7 (DAKO 
M7018; DAKO Tokyo, Japan; 1:300), CK-19 (DAKO M0888; 
DAKO Tokyo, Japan; 1:100), and thyroglobulin (Envision 
FLEX-Thyroglobulin, IR509; DAKO Tokyo, Japan; 1:200). 
Slides were incubated with the primary antibody for 30 min 
at room temperature. Immunoreactivity was detected using 
an indirect streptavidin-biotin method (LSAB kit; DAKO, 
Tokyo, Japan) and horseradish peroxidase. Bound antibody 
was detected as a brown stain. 
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We performed a search on PubMed using the terms ‘thyroid 
cancer’, ‘pleural fluid’, and ‘pleuritis’ to identify similar cases, 
restricting the papers to those published in English. The 
articles detected are shown in References (Reference no. 3-19). 
Fifty‑one patients of pleural fluid due to thyroid cancer were 
confirmed. Clinicopathological features of these patients were 
shown in Table I.
Case report
A 91-year-old male presented to the hospital with a 1-mo 
history of dyspnea on effort, which had worsened progressively 
over the previous few days. He had a 68-year history of tuber-
culaous pleuritis of the left and a 6-year history of surgically 
treated thyroid cancer. Physical examination showed that he 
was afebrile and had poor performance status. Neck examina-
tion showed well-healed cervical scars without adenopathy and 
chest examination showed dullness on the right side occupying 
one third of the chest. The peripheral blood test did not show 
leukocytosis and elevated levels of C-reactive protein, carci-
noembryonic antigen, and CA19-9. A chest radiograph showed 
thickening and calcification of the left pleura, and small 
nodules in both lungs with pleural fluid in the right. Chest CT 
revealed massive right pleural fluid causing atelectasis of the 
right lung and shift of the mediastinum to the left side. Chest 
radiograph and chest CT scan also showed thickening and 
calcification of the left pleura, and well‑circumscribed nodules 
measuring up to 15 mm in both lungs (Fig. 1). Primary or 
metastatic pulmonary cancer with pleural fluid, or recurrence 
of tuberculosis was highly suspected. Thoracentesis of pleural 
fluid was performed to alleviate severe dyspnea, yielding a 
serous fluid with malignant cells on cytological examination. 
Cancer cells, which had intra-nuclear inclusion body, were 
found in pleural fluid, and immunocytochemical staining 
of the cells was positive for cytokeratin (CK)-7, CK-19, and 
positive for thyroglobulin (Fig. 2). The diagnosis of massive 
pleural fluid due to metastatic papillary thyroid cancer was 
established. The patient's poor general condition and refusal 
prevented us from further treatment. Thereafter, the patient 
followed up with palliative care and died of the disease one 
month after the diagnosis of pleural fluid due to thyroid cancer. 
Diagnosis of pleural fluid due to papillary thyroid cancer was 
confirmed at autopsy. Informed patient consent was obtained 
from the family of the patient.
Discussion
Massive pleural fluid caused by thyroid cancer is very 
rare. To our best knowledge, there have been reported only 
51 cases (3-19). According to a review by Vassilopoulou-Sellin 
and Sneige at the MD Anderson Cancer Center, 10 (0.6%) 
had malignant pleural fluid that developed during the course 
of the disease among 1772 differentiated papillary thyroid 
cancer patients (4). In a recent review by Olson et al at the 
Johns Hopkins Hospital, only 6 patients with pleural fluid 
resulting from metastasis of thyroid primaries over the last 
26 years, which comprised 0.67% of all malignant pleural 
fluids (11). Most of the 21 patients had papillary thyroid cancer 
except for a few cases with both papillary and undifferentiated 
carcinomas (19), follicular thyroid cancer (16) and Hürthle cell 
thyroid cancer (9), which is usually classified with a certain 
type of follicular thyroid cancer (9). In our case, we compared 
the pathological findings of the specimens obtained from 
pleural fluids and those surgically resected specimens, which 
were 6-year previously in our hospital. They were consis-
tent and confirm the diagnosis of papillary thyroid cancer. 
Vassilopoulou‑Sellin and Sneige reported that pleural fluid 
appeared 61 to 132 months after the initial diagnosis of thyroid 
cancer in 4 patients (4). Together with the result of our case, 
these facts imply that pleural fluid may develop in long‑term 
survivors with this disease. 
With regards to distant metastases, Vassilopoulou-Sellin 
and Sneige reported that all their 10 patients had radiologically 
apparent lung metastases at the time pleural fluid was found (4). 
Other reports also pointed out lung metastases (3,5,7,12‑14,17). 
Vernon et al reported a patient with a left iliac crest metas-
tasis and multiple bilateral pulmonary metastases were also 
found (5). On the other hand, only one of the 6 patients had bone 
metastases, but others had no pathological evidence of distant 
metastasis in their institutional review by Olson et al (11). Our 
patient had multiple bilateral pulmonary metastases, which had 
been detected a few months prior to the pleural fluid.
The diagnosis of massive pleural fluid in our patient was 
not difficult with pleural immunocytochemical findings. In 
general, however, it may be difficult because of its rarity of 
pleural dissemination from thyroid cancer and the similarity 
of the symptoms and signs to those of advanced chronic 
Figure 1. Chest radiograph (A) and chest CT scan (B) showed massive 
pleural fluid in the right, thickening and calcification of the left pleura, and 
well-circumscribed nodules measuring up to 15 mm in both lungs.
Figure 2. Cell pellet sample obtained by needle aspiration showed cancer 
cells with intranuclear inclusion body (Papanicoloau staining) (A, 400x), and 
immunocytochemical staining of the cells was positive for cytokeratin (CK)-7 
(B, 400x), CK‑19, and positive for thyroglobulin (C, 400x).
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pulmonary diseases. Negative cytological results of pleural 
fluid might be required in evaluation of differential diagnosis 
of other causes of pleural fluid. Our patient had a history 
of tuberculous pleuritis, therefore, we had to include it as a 
differential diagnosis.
As for the therapy, in general, in patients with pleural fluid 
due to chemo-sensitive cancers, systemic chemotherapy is 
indicative for them (23-25). In those with chemo-insensitive 
cancers, on the other hand, chest tube drainage and pleurodesis 
are treatment choices for them (23-25). Vassilopoulou-Sellin 
and Sneige reported that pleural fluids in their patients were 
treated with local radioisotopes or sclerosing agents, systemic 
radioiodine or chemotherapy, or both (4). They also reported that 
appearance of pleural fluid preceded death by 1 to 20 months 
(median, 11 months) and pleural fluid was associated with 
greatly shortened survival time in all cases (3,4,7,9‑11,14‑19). 
In our patient, chest tube drainage and pleurodesis were 
considered, but only thoracentesis was performed because of 
his contra‑lateral calcified pleural thickening and poor respira-
tory condition and died of thyroid cancer one month after the 
diagnosis of pleural fluid.
In summary, pleural metastasis from papillary thyroid 
cancer is a potential cause of massive pleural fluid, although 
very rare. The current case extended the clinical spectrum of 
metastatic potential to the pleura of papillary thyroid cancer. 
As for the therapy, long-term palliation can be the treatment 
choice for these patients as there has not established any 
standard therapy for them. 
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